This inventor holds 1 USPTO granted patent and 1 published patent application and 1 EPO patent. Top assignee: Hoffmann-La Roche Inc.. Active years: 2025.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2025
Title: Tony Kam-thong: Innovator in Hepatitis B Treatment
Introduction: Tony Kam-thong is an inventor based in Basel, Switzerland. He is currently associated with F. Hoffmann-La Roche AG, a leading global healthcare company. Although he has not yet been granted any patents, his work focuses on significant advancements in the treatment of chronic HBV infections.
Latest Patent Applications: Tony Kam-thong's notable patent application is titled "Oligonucleotides for Modulating RTEL1 Expression." This invention relates to a RTEL1 inhibitor designed for use in treating HBV infections, particularly chronic HBV infections. The application emphasizes the use of RTEL1 inhibitors to destabilize cccDNA, such as HBV cccDNA. Additionally, it includes antisense oligonucleotides that are complementary to RTEL1 and capable of reducing RTEL1 mRNA. The invention also encompasses a pharmaceutical composition and its application in the treatment and/or prevention of HBV infections.
Conclusion: Tony Kam-thong is making strides in the field of hepatitis B treatment through his innovative research and patent applications. His contributions could potentially lead to significant advancements in managing chronic HBV infections.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile